Compass Pathways

Compass Pathways is a company listed under the stock ticker CMPS (GB).

View the org chart displaying its 27 main executives

Most searched biographies at Compass Pathways

• Kabir Nath, Chief Executive Officer
• Thomas Lonngren, Director
• Linda McGoldrick, Director

Popular executive movements at Compass Pathways

• Lori Englebert will join the company as Chief Commercial Officer on Jul. 8, 2024  (posted on June 27 2024).
• David Norton, who was Lead Director, is promoted to Interim Chairman of the Board  (posted on March 30 2024).
• Ekaterina Malievskaia, Director, has left the company  (posted on March 30 2024).

Click here to view some more movements at Compass Pathways

Create your alert
to follow the executive moves at Compass Pathways.

Compass Pathways has 2,294 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Eurofins PSS Insourcing Solutions (United States (USA)).

Popular M&A news in Biotechnology

• Biogen has announced the acquisition of HI-Bio  (posted on July 3 2024).
• N-Power Medicine has just announced a $72 Million fundraising (posted on July 2 2024).
• LB Pharmaceuticals has just announced a $75 Million fundraising (posted on June 28 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Kristina Burow - Director at Scholar Rock
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Compass Pathways

• Mental Health Care News, Articles & Stories from Compass Pathways
• Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry | Compass Pathways
• Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center | Compass Pathways
• Mental Health Care News, Articles & Stories from Compass Pathways
• Mental Health Care News, Articles & Stories from Compass Pathways
• COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression | COMPASS Pathways
• COMP360 psilocybin treatment in TRD with antidepressants | COMPASS Pathways
• COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology | COMPASS Pathways
• Data demonstrating long-term improvement in depression in cancer patients following single dose of COMP360 psilocybin therapy to be presented at ASCO 2023 | COMPASS Pathways
• Mental Health Care News, Articles & Stories from Compass Pathways
• View more press releases Close

Social media about Compass Pathways

• Compass Pathways on Wikipedia, Google News & Yahoo Finance
• Compass Pathways on LinkedIn, Twitter & YouTube

Contact by email its executives including Kabir Nath

Call Compass Pathways at +44...

View the org chart

Register to receive your alert

Report an error